|Alnylam Pharmaceuticals Inc., of Cambridge, Mass.||Onpattro (patisiran)||RNAi therapeutic||Hereditary transthyretin-mediated amyloidosis||Approved by Brazilian Health Regulatory Agency (ANVISA)|
|Kiadis Pharma NV, of Amsterdam||Off-the-shelf natural killer cells from universal donors||Off-the-shelf natural killer cells from universal donors||Acute myeloid leukemia||FDA cleared clinical study by the Ohio State University in relapsed/refractory AML|
|Puma Biotechnology Inc., of Los Angeles||Nerlynx (neratinib)||HER2-targeting therapy||Breast cancer||FDA approved a supplemental NDA for use in combination with capecitabine for treatment of adults with advanced or metastatic HER2-positive disease who have received 2 or more prior anti-HER2-based regimens in the metastatic setting|
|Translate Bio Inc., of Lexington, Mass.||MRT-5005||mRNA therapeutic||Cystic fibrosis||FDA granted fast track designation|
For more information about individual companies and/or products, see Cortellis.